{"nctId":"NCT01190228","briefTitle":"Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV","startDateStruct":{"date":"2010-08-25","type":"ACTUAL"},"conditions":["Japanese Encephalitis","Varicella"],"count":454,"armGroups":[{"label":"Group 1: JE-CV Vaccine Booster","type":"EXPERIMENTAL","interventionNames":["Biological: JE-CV Vaccine"]},{"label":"Group 2: JE-CV Vaccine First Dose","type":"EXPERIMENTAL","interventionNames":["Biological: JE-CV Vaccine"]},{"label":"Group 3: Varicella Vaccine","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Varicella Vaccine"]}],"interventions":[{"name":"JE-CV Vaccine","otherNames":["IMOJEV"]},{"name":"Varicella Vaccine","otherNames":["OKAVAX®"]}],"eligibilityModule":{"eligibilityCriteria":"An individual had to fulfill all of the following criteria in order to be eligible for trial enrollment:\n\nAll Participants\n\n* Aged 36 to 42 months on the day of inclusion\n* Provision of Informed Consent Form signed by at least one parent or other legally acceptable representative\n* Participant and parent/legally acceptable representative or guardian able to attend all scheduled visits and to comply with all trial procedures\n* In good general health, based on medical history and physical examination\n\nFor JE-CV vaccine primed group only\n\n* Participant who was vaccinated with JE-CV in JEC02 trial (NCT00735644)\n\nAn individual fulfilling any of the following criteria was excluded from trial enrollment:\n\nAll Participants\n\n* Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the trial vaccination\n* Planned participation in another clinical trial during the Day 0 - Month 6 period and for Group 1 up to 5 years for any flavivirus vaccine trial\n* Receipt of any vaccine\\* in the 4 weeks preceding the trial vaccination, except for pandemic influenza vaccination, which may be received at least 2 weeks before study vaccines\n* Planned receipt of any vaccine\\* in the 4 weeks following the trial vaccination, except for pandemic influenza vaccine. In the event of local or national immunization program with a pandemic influenza vaccine, participants who receive a pandemic influenza vaccine at any time during the trial will not be withdrawn from the trial.\n* Planned receipt of any JE vaccine during the course of the trial\n* Administration of any anti-viral within 2 months preceding the trial vaccination and up to 4 weeks following the trial vaccination\n* Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)\n* Seropositivity for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C, as reported by the parent/legally acceptable representative\n* History of central nervous system disorder or disease, including seizures and febrile seizures\n* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances\n* Chronic illness or any underlying illness (such as cardiovascular, kidney, liver or hematological disease or development abnormalities) that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion\n\n  * Except in case of national immunization days with oral polio vaccine\n\nFor JE-CV primed participants only\n\n* Receipt of any JE vaccine other than JE-CV during JEC02 trial(NCT00735644) and since the end of JEC02 trial\n\nFor JE-CV naïve participants only\n\n* Previous vaccination against flavivirus disease including JE\n* History of flavivirus infection either based on clinical suspicion or laboratory proven\n* Previous vaccination against varicella\n* Previous vaccination with JE-CV in JEC02 study\n* History of varicella, confirmed either clinically, serologically, or microbiologically\n* Known systemic hypersensitivity or anaphylactic/anaphylactoid reaction to neomycin.\n* Known history of thrombocytopenia or idiopathic thrombocytopenic purpura\n\nTemporary Contraindications:\n\nA prospective participant was not to be included in the study until the following conditions and/or symptoms had resolved:\n\n1. Receipt of oral or injected antibiotic therapy within 72 hours prior to the first blood draw (for Groups 1 and 2)\n2. Febrile illness (temperature ≥38.0°C \\[≥100.4°F\\]) or moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination (for all participants)\n\nThe Investigator was to postpone vaccination until the situation/condition resolved. Vaccination could be postponed within the timeframe for vaccination indicated in the protocol trial flowchart.","healthyVolunteers":true,"sex":"ALL","minimumAge":"36 Months","maximumAge":"42 Months","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With JE Seroprotection Before and Following a Dose of Live Attenuated JE-CV","description":"The presence of JE virus neutralizing antibodies was measured using a 50% plaque reduction neutralization test (PRNT50). Seroprotection status for antibody levels against JE virus before (on Day 0) and after JE-CV vaccination (Day 7 and Day 28) was defined as neutralizing antibody titer ≥ 10 (1/dilution).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.2","spread":null},{"groupId":"OG001","value":"15.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"89.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With JE Seroconversion Following a Dose of Live Attenuated JE-CV Vaccine","description":"The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay. Seroconversion was defined as participants with a pre-vaccination titer \\<10 (1/dilution) and post-vaccination titer ≥10 (1/dilution, or participants with pre vaccination titer ≥10 (1/dilution) and a ≥4-fold increase from pre- to post-vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.8","spread":null},{"groupId":"OG001","value":"15.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"89.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Summary of Geometric Mean Titers of JE Virus Antibodies Following a Dose of Live Attenuated JE-CV","description":"The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.4","spread":null},{"groupId":"OG001","value":"5.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"231","spread":null},{"groupId":"OG001","value":"6.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2242","spread":null},{"groupId":"OG001","value":"178","spread":null}]}]}]},{"type":"PRIMARY","title":"Summary of Geometric Mean Titer Ratios of JE Virus Antibodies Following a Dose of Live Attenuated JE-CV","description":"The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.87","spread":null},{"groupId":"OG001","value":"1.28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.0","spread":null},{"groupId":"OG001","value":"35.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Summary of Serological Flavivirus Status at Baseline of Participants Vaccinated With a Dose of Live Attenuated JE-CV","description":"The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay. Flavivirus positive was defined as titers against JE virus ≥10 (1/dilution) or titers against at least 1 dengue serotype ≥10 (1/dilution). Flavivirus negative was defined as titers against JE virus \\<10 (1/dilution) and titers against the 4 dengue serotypes \\<10 (1/dilution).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"289","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"277","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With JE Seroprotection Before and Up to 5 Years Following a Booster Dose of Live Attenuated JE-CV","description":"The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay. Seroprotection status for antibody levels against JE virus before (on Day 0) and after JE-CV vaccination (Days 7 and 28 and Years 1, 2, 3, 4, and 5) was defined as neutralizing antibody titer ≥ 10 (1/dilution).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Summary of Geometric Mean Titer of JE Virus Antibodies Before and Up to 5 Years Following a Booster Dose of Live Attenuated JE-CV","description":"The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"233","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2259","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"596","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"368","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"301","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"249","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null}]}]}]},{"type":"PRIMARY","title":"Summary of Geometric Mean Titer Ratios of JE Virus Antibodies Up to 5 Years Following a Booster Dose of Live Attenuated JE-CV","description":"The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.615","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.821","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.827","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.646","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Injection-Site Reactions and Systemic Reactions Following a Dose of Live Attenuated JE-CV or Varicella Vaccine","description":"Injection-site reactions: Pain, Erythema, and Swelling. Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia. Grade 3 Injection-site reactions: Pain, Incapacitating, unable to perform usual activities. Erythema and Swelling, ≥5 cm. Grade 3 Systemic reactions: Fever, 39.0°C; Headache, Malaise, and Myalgia, Significant; prevents daily activities.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":345},"commonTop":["Injection site Pain","Malaise","Fever","Headache","Upper respiratory tract infection"]}}}